Payment overview · 2025
General Payments
$1,143.70
65 reported records · 15 companies
Healthcare provider profile · identity verified
Travis Lee Page, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CALDWELL, ID · NPI 1396760385
Verified facts
What the public records show
CMS Open Payments records show Travis Lee Page, D.O. received $1,143.70 in general payments during 2025 across 65 reported records.
ABBVIE INC. accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Eliquis, Jardiance, Nurtec Odt, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Caplyta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $376.82 | 33.0% | 27 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $137.48 | 12.0% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $117.74 | 10.3% | 6 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $84.45 | 7.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $72.92 | 6.4% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.11 | 5.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.87 | 4.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.84 | 3.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.58 | 3.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.06 | 3.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.48 | 2.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.99 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.20 | 2.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.31 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.85 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,143.70 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $184.87 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $168.12 | 11 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $137.48 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $117.74 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $117.42 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $107.98 | 6 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $84.45 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $75.28 | 6 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $64.11 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $63.05 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.69 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.58 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.17 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.17 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.09 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 270 | 65 |
| Omeprazole | Omeprazole | 246 | 53 |
| Losartan Potassium | Losartan Potassium | 239 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 238 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 178 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 41 |
| Metformin Hcl | Metformin Hcl | 158 | 44 |
| Trazodone Hcl | Trazodone Hcl | 133 | 37 |
| Prednisone | Prednisone | 126 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 35 |
| Mounjaro | Tirzepatide | 106 | 20 |
| Gabapentin | Gabapentin | 99 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 25 |
| Ozempic | Semaglutide | 86 | 18 |
| Farxiga | Dapagliflozin Propanediol | 83 | 14 |
| Simvastatin | Simvastatin | 83 | 22 |
| Tramadol Hcl | Tramadol Hcl | 83 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 38 |
| Furosemide | Furosemide | 72 | 22 |
| Bupropion Xl | Bupropion Hcl | 71 | 15 |
| Azithromycin | Azithromycin | 67 | 53 |
| Meloxicam | Meloxicam | 62 | 23 |
| Spironolactone | Spironolactone | 58 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 14 |
| Carvedilol | Carvedilol | 54 | 14 |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Eliquis | Apixaban | 43 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 35 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 14 |
| Jardiance | Empagliflozin | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Diazepam | Diazepam | 19 | 14 |
| Finasteride | Finasteride | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 16 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Caplyta | Lumateperone Tosylate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,143.70 · 65 records | ABBVIE INC. | Auvelity, BOTOX, CAPLYTA, ELIQUIS, EVENITY, FANAPT, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, Symbravo, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XYOSTED, YUPELRI, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error